1919

Trading links with India established

1924

H J Foster & Co appointed sole agents

1926

Foster's becomes wholly-owned subsidiary of Joseph Nathan

1947

Secondary manufacture commences after war

1950

Name changed to Glaxo Laboratories

SmithKline & French appoints its first medical representative

1956

Primary production of vaccines begins at Worli

1960's

Infant foods manufactured at milk drying plant at Aligarh

Manufacturing facility for pharmaceuticals opened in Mumbai

1961

Vitamin A and betamethasone manufactured at new plant at Thane using imported raw materials

1968

Registered as a limited company. Animal health products introduced

1969

Indian shareholders acquire 25 per cent of the company's equity

1971

Research & development laboratory built at Thane

Relocation of the SmithKline & French plant from Mumbai to Bangalore

1983

Glaxo Group equity reduced from 75 per cent to 40 per cent Nashik factory commissioned

1984

SmithKline & Beecham becomes a public limited company under the new name of Eskayef Limited. Plant set up in Mysore for manufacture of bulk drugs

1985

The company's second basic drugs factory was inaugurated at Ankleshwar, Gujarat

1986

Joint venture projects Vegepro Foods and Feeds Limited and K G Gluco Biols were launched with equity participation of around 24 per cent by Glaxo India

1987

The company's name changed to Glindia Limited

1988

Production of bulk drug Ranitidine commenced at Ankleshwar

Hindustan Foods Limited, a joint venture project for the manufacture of extruded foods, was commissioned at Usgao, Goa with equity participation of 20 per cent by Glaxo and its subsidiaries

1989

Production of Zinetac at Nashik commenced

The company's name changed to Glaxo India Limited

1990

Production of the bulk drug, cephalexin, commenced at Ankleshwar and the salbutamol inhalers at Nashik

Glaxo rated amongst the first five of India's most respected companies (4th place), in a survey by Businessworld magazine

1991

An agreement was signed with the Council of Scientific and Industrial Research

Production of the bulk drug Griseofulvin commenced at Ankleshwar

Facilities commissioned at Nashik for the sterile dry filling of the injectable cephalosporins cefuroxime sodium and ceftazidime pentahydrate

1992

Liquid injectables block commissioned at Nashik

The company's trade investment in Vegepro and Feeds Limited was sold

1993

Glaxo Group raised its equity from 40 per cent to 51 per cent

The company sold its investment in Hindustan Foods Limited and Dempo Dairy Industries Limited

Cetzine, a second generation anti-histamine, and research product of UCB Pharma (Belgium), was launched under a co-marketing agreement

The company launched two anti-TB products - Zucox and Rizap

Manufacture of Beclomethasone inhalers commenced at Nashik

Thane Factory's new fermentation plan was inaugurated, making this site the largest Betamethasone producer in Glaxo Group

The company received recognition from the Ministry of Commerce as an export house

1994

Glaxo - Ankleshwar wins the Chief Executive's Trophy for Health Safety and Environment Management

Glaxo rated as India's 44th most valuable company in a survey conducted by Business Today

The company sold its Family Products Division to H J Heinz for a sum of Rs 210 crores. A formal agreement between the companies was signed and transaction was completed in October

Certificate of Merit awarded to Ankleshwar Factory for 'Excellence in Energy Conservation' by the Federation of Gujarat Mills and Industries (FGMI)

Voluntary Retirement Scheme introduced for Glaxo workmen

Eskayef Limited renamed SmithKline Beecham Pharmaceuticals India Ltd,

The Mysore plant receives ISO 9002 certification

The new Iodex plant inaugurated in Bangalore

1995

Glaxo - Thane won the Chief Executive's Trophy for Health Safety and Environmental Management

The company declares a Bonus in the ratio of 1:1

Voluntary Retirement Scheme introduced for Management Staff 1996 - 175 per cent record dividend declared

Change in distribution system - a Voluntary Retirement Scheme introduced at Branches and Depots

Government approved state-of-the-art Pharmacy Research & Development Centre (PR&D) inaugurated at Thane to cater to the unmet medical needs and to exploit local commercial opportunities

Glaxo rated amongst the top ten of India's most respected companies (8th place) in the Business World - Marg survey

Glaxo wins "Marketing Company of the Year" award from the Institute of Marketing & Management (IMM)

Glaxo wins "The Analyst" award from Chartered Analyst magazine as an investor rewarding company.

SmithKline Beecham’s Bangalore plant awarded the ISO 9002 certification

1997

Voluntary Retirement Scheme introduced for workmen at Worli and Thane

Glaxo acquires Biddle Sawyer Group of Companies subject to statutory approvals

1998

Biddle Sawyer acquisition is completed

Worli factory completes two million man-hours free from lost time accident

Gramin Arogya Vikas Sanstha - a rural development programme initiated in Nashik

Glaxo ranks 21st in Business Today's list of 500 most valuable companies

1999

Glaxo India completes 75 years of its operations in India

Glaxo India ranked as India's Most Respected Company by BusinessWorld. Glaxo took the top honour from amongst 229 companies surveyed by BusinessWorld - Indica Research

Glaxo India wins two Chairman's Awards for the year 1998 (announced in 1999) - The company's Community Support Programme won the Chairman's Award for "Excellence in Corporate Citizenship" and Glaxo India's Nashik Factory was chosen for the Health, Safety and Environmental Management Award

Nashik factory completes three million man-hours free from lost time accidents

Winner of the 1999 IMM (Institute of Marketing and Management) Award for Excellence as Marketing Company (organised sector)

The company's HIV / AIDS campaign in Press wins the first prize for the best "Social Responsibility Communication", awarded by the Association of Business Communicators of India (ABCI)

The Positive People Campaign entitled 'Real Friendships Don't Die with HIV' also wins the Global Award from the New York Festivals

2000

Agrivet Farm Care (AFC) tied up with Merial, the world's largest Animal Health Company, to market poultry vaccines

Glaxo India ranked 6th in 'Business Today' - Stern Stewart & Co. listing of India's best Wealth Creator Companies

Launches Seretide for Asthma

2001

Merger of SmithKline Beecham Pharmaceuticals (India) Limited into Glaxo India Limited. The name of the company changed to GlaxoSmithKline Pharmaceuticals Limited in India

2002

J P Garnier inaugurates GSK House

VRS at the Ankleshwar site and sale of Ankleshwar property to Glenmark Pharmaceuticals Limited

2003

GlaxoSmithKline named as India's most respected Pharmaceutical Company in a survey conducted by BusinessWorld and the Indian Market Research Bureau (IMRB)

Launches Cetzine (cetirizine; anti-histamine), Zimig (terbinafine; anti-infective), CCM (calcium citrate maleate; nutritional), Cobadex CZS (multivitamin with trace elements)

2004

“Augmentin?? becomes the No. 1 pharmaceutical brand, as rated by IMS

Launches Priorix (measles, mumps, rubella vaccine)

Receives prestigious “Multi Cultural Diversity Award?? from GlaxoSmithKline Consumer Healthcare Limited, U.S. for the ‘Famili Vaccines’ programme, selected from 83 entries received from markets world-wide

2005

Foundation stone laid for GSK vaccines plant at Nashik

Launch of oral contraceptives: Elogen (desogestrel and ethinylestradiol) and Zerogen (progesterone only pill)

Enters the diabetes therapeutic segment with the launch of Windia (rosiglitazone) and Windamet (rosiglitazone and metformin)

2006

Augmentin grows to a Rs. 100 crore brand

In-licensing alliance with Eisai Pharmaceuticals, Japan and launch of Parit (rabeprazole; gastrointestinal therapy area)

GlaxoSmithKline divests it’s Agrivet Farm Care (AFC) Business

2007

Launches Carzec (carvedilol) and Zemetril (cefprozil)

GlaxoSmithKline divests it’s Qualigens Fine Chemicals (QFC) Business

Launches Arixtra (fondaparinux sodium), an antithrombotic drug used in treating Deep Vein Thrombosis (DVT) and Acute Coronary Syndrome (ACS)

2008

Launches Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed), Infanrix (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine, Adsorbed) and Rotarix (Human Rotavirus Vaccine, Live Attenuated) vaccines

Launches Tykerb, a drug in combination with capecitabine, is indicated for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2+/neu (ErbB2+) and who have failed on prior therapy including trastuzumab

Launches Benitec (Olmersartan) and Benitec-H (Olmesartan + Hydrochlorothiazide) an anti-hypertensive drug in-licensed from Daiichi Sankyo Company Limited, Japan

2009

Launches Cervarix [Human Papillomavirus (Types 16 and 18)] vaccine

Launches Dermocalm for treatment of Dry Itchy skin

Commences Albendazole production in Nashik to treat Lymphatic Filariasis

2010

Launches Mycamine an injectible antifungal drug in-licensed from Astellas, Japan